Report of Foreign Issuer (6-k)
24 July 2019 - 8:38PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of July, 2019
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8
9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 24 July 2019, London UK - LSE
GlaxoSmithKline plc appoints Jonathan Symonds as Non-Executive
Chairman of the Board of Directors
GIaxoSmithKline plc (GSK) today announced that Jonathan Symonds
will succeed Sir Philip Hampton as Non-Executive Chairman of the
GSK Board with effect from 1
st
September
2019.
Jonathan is currently Deputy Group Chairman of HSBC Holdings plc
and has been an independent non-executive Director of HSBC since
April 2014. He is a former Chief Financial Officer of Novartis AG
and AstraZeneca plc, and has been a non-executive Director of
Diageo plc and QinetiQ plc. He is currently non-executive Chairman
of Proteus Digital Health Inc, a non-executive director of Rubius
Therapeutics Inc and Chairman of Genomics England
Limited.
The appointment was approved by the Board and follows a thorough
succession process undertaken by the Nominations Committee, led by
Vindi Banga, the company's Senior Independent Director (SID), in
which all the Non-Executive Directors
participated.
Vindi Banga said:
"Jon has exceptional experience in life
sciences, and in the financial management and governance of
major, global companies. Throughout his career he has demonstrated
a passion for science, and is known for his integrity and
professionalism. We are delighted that Jon will lead the Board
through this next phase for GSK, and we look forward to him
joining in September."
Jonathan Symonds said:
"I
am delighted to be joining GSK, at what is a really important time
for the company as it seeks to create value from its new R&D
approach, and to create two, new world-leading companies, one
focussed on Pharmaceuticals and Vaccines, the other on Consumer
Healthcare."
Victoria Whyte
Company Secretary
24 July 2019
Notes
1.
The
appointment of Jonathan Symonds was made by the Board on the
recommendation of the Nominations Committee which was chaired by
Vindi Banga, GSK's Senior Independent Non-Executive Director. The
Committee comprises: Vindi Banga, Judy Lewent, Lynn Elsenhans, and
Urs Rohner and is chaired by Philip Hampton. However, in accordance
with good governance Philip Hampton did not participate in this
process. Other Non-Executive Directors, who are not members of the
Committee also participated in the succession
process.
2.
The
Board determined that Jonathan Symonds is an independent
Non-Executive Director on appointment in accordance with the UK
Corporate Governance Code.
3.
The
Remuneration Committee agreed Jonathan Symonds fees. He will
receive total fees of £700,000 per annum comprising
£525,000 in cash together with GSK Ordinary Shares to the
value of £175,000.
4.
In
addition to being Chairman, Jonathan Symonds will also Chair the
company's Nominations Committee.
5.
Jonathan
Symonds does not have a service contract. He has a letter of
appointment which may be viewed by contacting the Company Secretary
at the Company's registered office.
6.
Once
he becomes Chairman, he will be based at GSK's registered office at
980 Great West Road, Brentford, Middlesex, TW8
9GS.
7.
HSBC
Holdings plc has announced that Jonathan Symonds will retire as
Non-Executive Director on 18
th
February
2020.
8.
There
are no additional details to disclose under the Listing Rule of
9.6.13R in respect of the appointment of Jonathan
Symonds.
9.
Sir
Philip Hampton will retire from the Board on 31
st
August
2019.
10.
From
1
st
September
2019 the Board of GSK will comprise:
|
Jonathan Symonds
|
Non-Executive Chairman
|
|
Ms Emma Walmsley
|
Chief Executive Officer
|
|
Mr Iain Mackay
|
Chief Financial Officer
|
|
Dr Hal Barron
|
Chief Scientific Officer and President, R&D
|
|
Mr Vindi Banga
|
Senior Independent Non-Executive Director
|
|
Dr Vivienne Cox
|
Independent Non-Executive Director
|
|
Ms Lynn Elsenhans
|
Independent Non-Executive Director
|
|
Dr Jesse Goodman
|
Independent Non-Executive Director
|
|
Dr Laurie Glimcher
|
Independent Non-Executive Director
|
|
Ms Judy Lewent
|
Independent Non-Executive Director
|
|
Mr Urs Rohner
|
Independent Non-Executive Director
|
About GSK
GSK is a science-led global healthcare company with a special
purpose: to help people do more, feel better, live
longer.
|
GSK enquiries:
|
|
|
|
|
|
UK
Media enquiries:
|
Simon
Steel
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
|
Mary
Hinks-Edwards
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
|
|
|
|
|
|
US
Media enquiries:
|
Kristen
Neese
|
+1
(804) 217-8147
|
(Philadelphia)
|
|
|
|
|
|
|
|
|
Analyst/Investor
enquiries:
|
Sarah
Elton-Farr
|
+44 (0)
208 047 5194
|
(London)
|
|
|
|
Danielle
Smith
|
+44 (0)
20 8047 7562
|
(London)
|
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
Cautionary statement regarding forward-looking
statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
'Principal risks and uncertainties' in the company's Annual Report
on Form 20-F for 2018.
|
|
Registered in England & Wales:
No.
3888792
|
|
|
|
|
|
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: July
24, 2019
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2024 to Nov 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Nov 2023 to Nov 2024
